NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Hot Flashes in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled Study

被引：0

作者：

Simon, James ^{[3
,4
]}

Anderson, Richard ^{[2
]}

Ballantyne, Elizabeth ^{[1
]}

Joffe, Hadine ^{[5
,6
]}

Kerr, Mary ^{[1
]}

Lumsden, Mary Ann ^{[7
]}

Panay, Nicholas ^{[8
]}

Seymore, Susan ^{[1
]}

Trower, Mike ^{[1
]}

Pawsey, Stephen ^{[1
]}

机构：

[1] KaNDy Therapeut Ltd, Stevenage, Herts, England

[2] Univ Edinburgh, Edinburgh, Midlothian, Scotland

[3] George Washington Univ, Washington, DC USA

[4] IntimMedicine, Washington, DC USA

[5] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[6] Harvard Med Sch, Boston, MA 02115 USA

[7] Univ Glasgow, Glasgow, Lanark, Scotland

[8] Imperial Coll, London, England

来源：

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2020年 / 27卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

S-21

引用

页码：1461 / 1461

页数：1

共 14 条

[1] NT-814, a Non-hormonal Dual NK1,3 Receptor Antagonist Markedly Improves Sleep, Mood and Quality of Life in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled Study (SWITCH-1)
Joffe, Hadine
Pawsey, Stephen
Anderson, Richard
Ballantyne, Elizabeth
Kerr, Mary
Lumsden, Mary Ann
Panay, Nicholas
Seymore, Susan
Simon, James
Trower, Mike
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (12): : 1456 - 1457
[2] Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial
Trower, Mike
Anderson, Richard A.
Ballantyne, Elizabeth
Joffe, Hadine
Kerr, Mary
Pawsey, Steve
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (05): : 498 - 505
[3] NT-814, a novel dual NK1,3 receptor antagonist results in immediate improvements in bothersome post-menopausal symptoms.
Pawsey, Stephen
Ballantyne, Elizabeth
Trower, Mike
Kerr, Mary
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2018, 25 (12): : 1492 - 1493
[4] Efficacy of a Non-Hormonal Treatment, BRN-01, on Menopausal Hot Flashes A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Colau, Jean-Claude
Vincent, Stephane
Marijnen, Philippe
Allaert, Francois-Andre
DRUGS IN R&D, 2012, 12 (03) : 107 - 119
[5] Efficacy of a non-hormonal treatment, BRN-01, on menopausal hot flashes: A multicenter, randomized, double-blind, placebo-controlled trial
Colau J.-C.
Vincent S.
Marijnen P.
Allaert F.-A.
Drugs in R&D, 2012, 12 (3) : 107 - 119
[6] Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial
Prague, Julia K.
Roberts, Rachel E.
Comninos, Alexander N.
Clarke, Sophie
Jayasena, Channa N.
Nash, Zachary
Doyle, Chedie
Papadopoulou, Deborah A.
Bloom, Stephen R.
Mohideen, Pharis
Panay, Nicholas
Hunter, Myra S.
Veldhuis, Johannes D.
Webber, Lorraine C.
Huson, Les
Dhillo, Waljit S.
LANCET, 2017, 389 (10081): : 1809 - 1820
[7] The Neurokinin 3 Receptor Antagonist, Fezolinetant, is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
Fraser, Graeme
Lederman, Samuel
Waldbaum, Arthur
Lee, Misun
Skillern, Laurence
Ramael, Steven
JOURNAL OF WOMENS HEALTH, 2019, 28 (06) : 15 - 15
[8] Neurokinin 3 receptor antagonism is a highly effective, novel treatment for menopausal hot flushes with rapid onset: a phase 2, randomised, double-blind, placebo-controlled trial
Prague, Julia K.
Roberts, Rachel E.
Comninos, Alexander N.
Clarke, Sophie
Jayasena, Channa N.
Nash, Zachary
Doyle, Chedie
Papadopoulou, Deborah
Bloom, Stephen R.
Mohideen, Pharis
Lin, Vivian
Stern, Theresa
Panay, Nicholas
Hunter, Myra S.
Veldhuis, Johannes D.
Webber, Lorraine C.
Huson, Les
Dhillo, Waljit S.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2017, 24 (12): : 1429 - 1430
[9] Effect of the Neurokinin 3 Receptor Antagonist Fezolinetant on Menopausal Vasomotor Symptoms and Patient-Reported Outcomes: Results of a Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
Santoro, Nanette
Waldbaum, Arthur
Lederman, Samuel
Fraser, Graeme L.
Lademacher, Christopher
Skillern, Laurence
Young, James
Ramael, Steven
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (12): : 1454 - 1454
[10] Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
Tsai, Chia-Kuang
Chen, Yuan-Yuei
Chou, Chung-Hsing
Kao, Tung-Wei
Liang, Chih-Sung
Yang, Fu-Chi
Wang, Chung-Ching
Lee, Jiunn-Tay
Chen, Wei-Liang
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (12): : 1357 - 1362

← 1 2 →